Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)

Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia

Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference

Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates

Synlogic Announces Second Quarter 2019 Conference Call and Webcast

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development

Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines

Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update

Synlogic Announces First Quarter 2019 Conference Call and Webcast

Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)